Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children and Adolescents from 2003 to 2023: a Plain Language Summary of Publication.
Stuurman AL, Enxing J, Gutiérrez AV, Gray CM, Sepúlveda-Pachón IT, Ubamadu E, Bandell A, Taylor S, El Azzi G, Meeraus W. Stuurman AL, et al. Ther Adv Infect Dis. 2025 Oct 17;12:20499361251390680. doi: 10.1177/20499361251390680. eCollection 2025 Jan-Dec. Ther Adv Infect Dis. 2025. PMID: 41132317 Free PMC article. Review.
Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis.
Stuurman AL, Enxing J, Gutiérrez AV, Gray CM, Sepúlveda-Pachón IT, Ubamadu E, Bandell A, Taylor S, El Azzi G, Meeraus W. Stuurman AL, et al. Expert Rev Vaccines. 2025 Dec;24(1):703-725. doi: 10.1080/14760584.2025.2536087. Epub 2025 Jul 30. Expert Rev Vaccines. 2025. PMID: 40697050 Free article.
COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron.
Meeraus W, Stuurman AL, Durukal I, Conde-Sousa E, Lee A, Maria AS, Furtado BE, Ouwens M, Gray CM, Valverde DA, da Silva HG, Taylor S. Meeraus W, et al. Among authors: stuurman al. Vaccine. 2023 Oct 6;41(42):6366-6378. doi: 10.1016/j.vaccine.2023.08.085. Epub 2023 Sep 12. Vaccine. 2023. PMID: 37704499 Free article.
Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis.
Meeraus W, de Munter L, Gray CM, Dwivedi A, Wyndham-Thomas C, Ouwens M, Hartig-Merkel W, Drikite L, Rebry G, Carmona A, Stuurman AL, Chi Nguyen TY, Mena G, Mira-Iglesias A, Icardi G, Otero-Romero S, Baumgartner S, Martin C, Taylor S, Bollaerts K. Meeraus W, et al. Among authors: stuurman al. Lancet Reg Health Eur. 2023 Jul 1;31:100675. doi: 10.1016/j.lanepe.2023.100675. eCollection 2023 Aug. Lancet Reg Health Eur. 2023. PMID: 37547274 Free PMC article.
Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform.
Stuurman AL, Carmona A, Biccler J, Descamps A, Levi M, Baum U, Mira-Iglesias A, Bellino S, Hoang U, de Lusignan S, Bonaiuti R, Lina B, Rizzo C, Nohynek H, Díez-Domingo J; DRIVE Study Contributors. Stuurman AL, et al. Front Public Health. 2023 Jul 20;11:1195409. doi: 10.3389/fpubh.2023.1195409. eCollection 2023. Front Public Health. 2023. PMID: 37546295 Free PMC article.
Investigating confounding in network-based test-negative design influenza vaccine effectiveness studies-Experience from the DRIVE project.
Stuurman AL, Levi M, Beutels P, Bricout H, Descamps A, Dos Santos G, McGovern I, Mira-Iglesias A, Nauta J, Torcel-Pagnon L, Biccler J; DRIVE consortium. Stuurman AL, et al. Influenza Other Respir Viruses. 2023 Jan;17(1):e13087. doi: 10.1111/irv.13087. Epub 2022 Dec 22. Influenza Other Respir Viruses. 2023. PMID: 36550627 Free PMC article.
Estimating baseline rates of adverse perinatal and neonatal outcomes using a facility-based surveillance approach: A prospective observational study from the WHO Global Vaccine Safety Multi-Country Collaboration on safety in pregnancy.
Sharan A, Stuurman AL, Jahagirdar S, Elango V, Riera-Montes M, Kashyap NK, Biccler J, Poluru R, Arora NK, Mathai M, Mangtani P, Devlieger H, Anderson S, Whitaker B, Wong HL, Moran A, Maure CG; WHO Global Vaccine Safety Multi-Country Collaboration sites. Sharan A, et al. Among authors: stuurman al. EClinicalMedicine. 2022 Jun 17;50:101506. doi: 10.1016/j.eclinm.2022.101506. eCollection 2022 Aug. EClinicalMedicine. 2022. PMID: 35770255 Free PMC article.
Operational lessons learned in conducting an international study on pharmacovigilance in pregnancy in resource-constrained settings: The WHO Global Vaccine safety Multi-Country collaboration project.
Sharan A, Jahagirdar S, Stuurman AL, Elango V, Riera-Montes M, Kumar Kashyap N, Kumar Arora N, Mathai M, Mangtani P, Devlieger H, Anderson S, Whitaker B, Wong HL, Cutland CL, Guillard Maure C; WHO Global Vaccine Safety Multi-Country Collaboration Sites. Sharan A, et al. Among authors: stuurman al. Vaccine X. 2022 Aug;11:100160. doi: 10.1016/j.jvacx.2022.100160. Epub 2022 Apr 9. Vaccine X. 2022. PMID: 35434599 Free PMC article.
WHO global vaccine safety multi-country collaboration project on safety in pregnancy: Assessing the level of diagnostic certainty using standardized case definitions for perinatal and neonatal outcomes and maternal immunization.
Stuurman AL, Sharan A, Jahagirdar S, Elango V, Riera-Montes M, Kashyap N, Biccler J, Poluru R, Arora N, Mathai M, Mangtani P, DeVlieger H, Anderson S, Whitaker B, Wong HL, Cutland C, Guillard Maure C; WHO GVS MCC Sites. Stuurman AL, et al. Vaccine X. 2021 Nov 3;9:100123. doi: 10.1016/j.jvacx.2021.100123. eCollection 2021 Dec. Vaccine X. 2021. PMID: 34825164 Free PMC article.
21 results